Abstract
Aims Increased left atrial (LA) volume is a known risk factor for atrial fibrillation (AF). There is also emerging evidence that alterations in LA function due to an atrial cardiomyopathy are associated with an increased risk of AF. The availability of large-scale cardiac MRI data paired with genetic data provides a unique opportunity to assess the joint genetic contributions of LA structure and function to AF risk.
Methods and results We developed deep learning models to measure LA traits from cardiovascular magnetic resonance imaging (MRI) in 40,558 UK Biobank participants and integrated these data to estimate LA minimum (LAmin), maximum (LAmax), and stroke volume (LASV), as well as emptying fraction (LAEF). We conducted a genome-wide association study (GWAS) in 35,049 participants without pre-existing cardiovascular disease, identifying 20 common genetic loci associated with LA traits. Eight of the loci associated with LA traits were previously associated with AF: the AF risk alleles were associated with an increased LA minimum volume (LAmin) and a decreased LAEF. A Mendelian randomization analysis confirmed that AF causally affects LA volume (IVW P = 6.2E-06), and provided evidence that LAmin causally affects AF risk (IVW P = 4.7E-05). In UK Biobank participants, a polygenic prediction of LAmin was significantly associated with risk for AF (HR 1.09 per SD; P = 1.6E-36) and ischemic stroke (HR 1.04 per SD; P = 4.7E-03).
Conclusions We performed the largest and highest resolution assessment of LA structure and function to date. We then identified 20 common genetic variants associated with LA volumes or LAEF, 19 of which were novel. We found that a polygenic prediction of the minimal LA volume was associated with AF and stroke. Finally, we found an inverse relation between genetic variants associated with AF risk and LAEF. Our findings provide evidence of a causal relation between LA contractile function and AF.
Competing Interest Statement
Dr. Pirruccello has served as a consultant for Maze Therapeutics. Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration with IBM. Dr. Ng is employed by IBM Research. Dr. Ho is supported by a grant from Bayer AG focused on machine-learning and cardiovascular disease and a research grant from Gilead Sciences. Dr. Ho has received research supplies from EcoNugenics. Dr. Philippakis is employed as a Venture Partner at GV; he is also supported by a grant from Bayer AG to the Broad Institute focused on machine learning for clinical trial design. Dr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases. Dr. Ellinor has also served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. Remaining authors report no disclosures.
Funding Statement
This work was supported by the Fondation Leducq (14CVD01), and by grants from the National Institutes of Health to Dr. Ellinor (1RO1HL092577, K24HL105780) and Dr. Ho (R01HL134893, R01HL140224, K24HL153669). This work was supported by a John S LaDue Memorial Fellowship and the Sarnoff Cardiovascular Research Foundation Scholar Award to Dr. Pirruccello. Dr. Nauffal is supported by NIH grant 5T32HL007604-35. Dr. Khurshid is supported by NIH grant T32HL007208. Dr. Lubitz is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. This work was supported by a grant from the American Heart Association Strategically Focused Research Networks to Dr. Ellinor. Dr. Lindsay is supported by the Fredman Fellowship for Aortic Disease and the Toomey Fund for Aortic Dissection Research. This work was funded by a collaboration between the Broad Institute and IBM Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to the UK Biobank was provided under application #7089 and approved by the Partners HealthCare institutional review board (protocol 2019P003144).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data are made available to researchers from research institutions with genuine research inquiries, following IRB and UK Biobank approval. GWAS summary statistics and polygenic score weights will be available upon publication at the Broad Institute Cardiovascular Disease Knowledge Portal ( http://www.broadcvdi.org ). LA measurements will be returned to the UK Biobank for use by any approved researcher. All other data are contained within the article and its supplementary information.
